outcomes of reduced intensity allosct in patients with accelerated-phase myelofibrosis
Published 2 years ago • 89 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
1:52
phase i dose-escalation study of the bet inhibitor incb057643 in r/r myelofibrosis
-
3:40
outcomes of all stratified by socioeconomic factors
-
0:59
the impact of age and comorbidities on the outcomes of patients with cll treated with btk inhibitors
-
3:34
dose-escalation results from phase ib/iia trial of azd4573 acalabrutinib in r/r dlbcl
-
8:15
cpg outcome assessment measures and treatment algorithms
-
29:00
anaphylaxis diagnosis & management
-
2:16
diagnosed with acute lymphoblastic leukemia at age four - morgan may's story
-
1:30
the prognostic value of patient-reported outcomes in mds
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
0:45
difference between quality of life & patient-reported outcomes
-
2:22
improve study: mrd assessment as an endpoint to define treatment length and intensity in cll
-
2:12
the impact of immuno-oncology on all outcomes
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
8:34
hct in mds: cell source and conditioning type
-
1:24
updated results from the momentum study assessing the efficacy of momelotinib in mf
-
5:07
daratumumab in the management of al amyloidosis
-
0:48
disparities in outcomes for patients with all
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
1:02
maintenance therapy following treatment for amyloidosis
-
0:47
overview of the phase iii enhance trial schema
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib